Genuinely exciting phase 3 results for CymaBay's seladelpar

Results from a phase 3 trial looking at treatment for primary biliary cholangitis (PBC) are 'genuinely exciting' and support the potential for seladelpar to raise the bar in treatment of the disease.

Related Keywords

Toronto , Ontario , Canada , Charles Mcwherter , Terry Horner , Cymabay Therapeutics Inc , Toronto Centre For Liver Disease , , Cymabay Therapeutics , New England Journal , Gideon Hirschfield , Terry Horner Chair , Toronto Centre , New Drug Application ,